Circulating hormones and risk of gastric cancer by subsite in three cohort studies.
Cancer
Gastric
Hormones
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
20
03
2023
accepted:
20
06
2023
medline:
13
11
2023
pubmed:
17
7
2023
entrez:
16
7
2023
Statut:
ppublish
Résumé
Obesity has been positively associated with gastric cancer. Excess fat impacts hormones, which have been implicated in carcinogenesis. We investigated obesity-related hormones and cardia gastric cancer (CGC) and non-cardia gastric cancer (NCGC) risk. Nested case-control studies were conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (61 CGCs, and 172 NCGCs and matched controls) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study (100 CGCs and 65 NCGCs and matched controls); serum hormones were measured. In UK-Biobank (n = 458,713), we included 137 CGCs and 92 NCGCs. Sex-specific analyses were conducted. For EPIC and ATBC, odds ratios (ORs), and for UK-Biobank hazard ratios (HRs), were estimated using conditional logistic regression and Cox regression, respectively. Insulin-like growth-factor-1 was positively associated with CGC and NCGC in EPIC men (OR Some obesity-related hormones influence CGC and NCGC risk.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity has been positively associated with gastric cancer. Excess fat impacts hormones, which have been implicated in carcinogenesis. We investigated obesity-related hormones and cardia gastric cancer (CGC) and non-cardia gastric cancer (NCGC) risk.
METHODS
METHODS
Nested case-control studies were conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (61 CGCs, and 172 NCGCs and matched controls) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study (100 CGCs and 65 NCGCs and matched controls); serum hormones were measured. In UK-Biobank (n = 458,713), we included 137 CGCs and 92 NCGCs. Sex-specific analyses were conducted. For EPIC and ATBC, odds ratios (ORs), and for UK-Biobank hazard ratios (HRs), were estimated using conditional logistic regression and Cox regression, respectively.
RESULTS
RESULTS
Insulin-like growth-factor-1 was positively associated with CGC and NCGC in EPIC men (OR
CONCLUSIONS
CONCLUSIONS
Some obesity-related hormones influence CGC and NCGC risk.
Identifiants
pubmed: 37455285
doi: 10.1007/s10120-023-01414-0
pii: 10.1007/s10120-023-01414-0
pmc: PMC10640529
doi:
Substances chimiques
Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
969-987Subventions
Organisme : Cancer Research UK
ID : 20189
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : Cancer Research UK
ID : EDDPMA-NOV22/100009
Pays : United Kingdom
Organisme : Cancer Research UK
ID : PRCRPG-NOV22/100001
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):466-72
pubmed: 15701829
J Natl Cancer Inst. 2019 Jan 1;111(1):34-41
pubmed: 29788475
Endocr Rev. 2007 Feb;28(1):20-47
pubmed: 16931767
Am J Gastroenterol. 2021 Mar 1;116(3):522-529
pubmed: 33156012
Diabet Med. 2013 Jul;30(7):803-17
pubmed: 23413806
J Natl Cancer Inst. 2011 Jul 20;103(14):1123-9
pubmed: 21693726
Carcinogenesis. 2009 Jan;30(1):71-7
pubmed: 19015200
Cancer Prev Res (Phila). 2021 Jun;14(6):659-666
pubmed: 33766833
Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):659-670
pubmed: 29970888
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):954-61
pubmed: 21415356
Obes Rev. 2007 Jan;8(1):21-34
pubmed: 17212793
Am J Epidemiol. 2010 Dec 15;172(12):1384-93
pubmed: 21051447
Gut Liver. 2019 Mar 15;13(2):133-134
pubmed: 30893982
Biomed Res Int. 2014;2014:658913
pubmed: 25110685
ESMO Open. 2020 Sep;5(5):e000728
pubmed: 32948630
Biochem Biophys Res Commun. 2014 Apr 18;446(4):822-9
pubmed: 24569072
Gastric Cancer. 2022 Jan;25(1):107-123
pubmed: 34554347
Int J Cancer. 2020 May 15;146(10):2728-2735
pubmed: 31351006
PLoS One. 2020 Oct 20;15(10):e0240413
pubmed: 33079929
Biochem Genet. 2021 Jun;59(3):652-667
pubmed: 33442814
Mol Cell Biochem. 2013 Oct;382(1-2):163-72
pubmed: 23807739
Int J Cancer. 2015 Mar 15;136(6):1402-10
pubmed: 25066446
Epidemiol Infect. 2002 Jun;128(3):411-7
pubmed: 12113485
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Mol Cell Biochem. 2014 Oct;395(1-2):99-107
pubmed: 24934239
Anticancer Agents Med Chem. 2013 Oct;13(8):1291-8
pubmed: 23547874
J Lipid Res. 2019 Oct;60(10):1710-1719
pubmed: 30097511
Br J Cancer. 2012 Jan 3;106(1):210-6
pubmed: 22127287
J Steroid Biochem Mol Biol. 1991;40(4-6):813-20
pubmed: 1659894
Anal Chem. 2015 Jul 21;87(14):7180-6
pubmed: 26090565
J Pathol. 2003 Nov;201(3):430-8
pubmed: 14595755
Arch Physiol Biochem. 2008 Feb;114(1):63-70
pubmed: 18465360
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
J Epidemiol. 2005 Jun;15 Suppl 2:S120-5
pubmed: 16127223
Am J Gastroenterol. 2021 Sep 1;116(9):1844-1852
pubmed: 34240714
Arch Med Res. 2021 Aug;52(6):660-664
pubmed: 33781580
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Arch Med Sci. 2015 Apr 25;11(2):346-52
pubmed: 25995751
Ann Epidemiol. 1994 Jan;4(1):1-10
pubmed: 8205268
Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2332-2342
pubmed: 32856611
Gut Liver. 2019 Mar 15;13(2):154-160
pubmed: 30400721
Mol Med Rep. 2016 Jul;14(1):705-14
pubmed: 27220727
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur Cytokine Netw. 2018 Jun 1;29(2):52-58
pubmed: 30078770
Int J Cancer. 2020 Feb 15;146(4):929-942
pubmed: 31050823
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1065-71
pubmed: 12376508
Eur J Cancer. 2007 Jul;43(10):1611-6
pubmed: 17532620